Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783950 · ClinicalTrials.gov registry record · NA
Genomics in Michigan Impacting Observation or Radiation
A NA study of Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 356
- Enrollment target
- 13
- Study locations
NCT02783950: Completed NA study of Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center.
NCT02783950 is a NA study of Prostate Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 356 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (41% lower). The trial reports 13 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02783950, a NA study of Prostate Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 356 participants
- Enrollment target
- 13
- Study locations
Study Summary
To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
Primary Outcome
Adjuvant will be defined as preceding biochemical recurrence (BCR) (i.e.: PSA ≥ 0.2 ng/ml) and within 18 months of radical prostatectomy.
Conditions Studied
Interventions
- OTHER Decipher Prostate Cancer Classifier
Study Locations (13)
Michigan
- University of Michigan Hospital and Health Systems - Ann Arbor
- Wayne State University/Karmanos Cancer Institute - Detroit
- Henry Ford Hospital - Detroit
- Urologic Consultants - Grand Rapids
- Urology Associates of Grand Rapids - Grand Rapids
- Michigan Urological Clinic - Grand Rapids
- Spectrum Health Medical Group- Urology - Grand Rapids
- Urology Surgeons, PC - Grand Rapids
- Comprehensive Medical Center, PLLC - Royal Oak
- Tri-City Urology - Saginaw
- Bay Area Urology Associates, PC - Traverse City
- Michigan Institute of Urology-Town Center - Troy
- IHA Urology at St. Joe's Ann Arbor - Ypsilanti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2017-01-17 |
| Est. Completion | 2024-04-02 |
| Phase | NA |
What the finished NCT02783950 record still lists
NCT02783950 is an interventional study that assigns participants to a tested intervention. The registered 356 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Decipher Prostate Cancer Classifier is the first listed.
NCT02783950 lists 13 locations in 1 state (Michigan).
Frequently Asked Questions
What is clinical trial NCT02783950 about?
NCT02783950 is a clinical study titled "Genomics in Michigan Impacting Observation or Radiation". To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
What is the current status of trial NCT02783950?
This trial is currently completed. It is a NA study. The enrollment target is 356 participants. The study started on 2017-01-17. Estimated completion is 2024-04-02.
What conditions does trial NCT02783950 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02783950?
The interventions under investigation include: Decipher Prostate Cancer Classifier (OTHER).
Who is sponsoring clinical trial NCT02783950?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02783950 being conducted?
This trial has 13 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02783950's enrollment target sits among peer trials
356 144th of 735 higher than 592 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06960993 · 356 participants · NA
Mosaic Trial for Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI